VYN-201 is under clinical development by VYNE Therapeutics and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VYN-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VYN-201 overview
VYN-201 is under development for the treatment of vitiligo, rheumatoid arthritis, idiopathic pulmonary fibrosis and psoriasis. It is administered topically in the form of gel, intraarticular and intranasal route. It is being developed based on bromodomain & extra-terminal (BET) domain (InhiBET) platform. It acts by targeting pan-bromodomain and extra-terminal domain (BET) proteins.
It was also under development for the treatment of eczema, macular degeneration, colitis, inflammation and unspecified indication.
VYNE Therapeutics overview
VYNE Therapeutics is a clinical-stage biopharmaceutical company that develops proprietary differentiated therapies for the treatment of immuno-inflammatory diseases. The company’s pipeline products include VYN201, VYN202 and FMX114 in the form of topical, inhalational and oral. Its VYN201 pipeline product treats nonsegmental vitiligo, rheumatological and lung diseases. The company’s VYN202 and FMX114 treat rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis (UC), crohn’s, multiple sclerosis (MS), myeloproliferative neoplastic disorders and atopic dermatitis. It develops drugs by using the InhiBET platform. VYNE Therapeutics is headquartered in Bridgewater, New Jersey, the US.
For a complete picture of VYN-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
